GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol).

Published in:

Therapeutic Advances in Medical Oncology, 2022, p. 1, doi. 10.1177/17588359221092486

By:

• Conduit, Ciara;
• Mak, Blossom;
• Qu, Wenjia;
• Lulio, Juliana Di;
• Burder, Ronan;
• Bressel, Matthias;
• Cusick, Thomas;
• Dhillon, Haryana M.;
• Lourenço, Richard De Abreu;
• Underhill, Craig;
• Torres, Javier;
• Crumbaker, Megan;
• Honeyball, Florian;
• Linton, Anthony;
• Allen, Ray;
• Davis, Ian D.;
• Clark, Susan J.;
• Horvath, Lisa G.;
• Mahon, Kate L.

Publication type:

Article